181 related articles for article (PubMed ID: 26765459)
1. Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma.
Andrici J; Goeppert B; Sioson L; Clarkson A; Renner M; Stenzinger A; Tayao M; Watson N; Farzin M; Toon CW; Smith RC; Mittal A; Samra JS; Hugh TJ; Chou A; Lawlor RT; Weichert W; Schirmacher P; Sperandio N; Ruzzenente A; Scarpa A; Gill AJ
Medicine (Baltimore); 2016 Jan; 95(2):e2491. PubMed ID: 26765459
[TBL] [Abstract][Full Text] [Related]
2. Intrahepatic cholangiocarcinoma frequently shows loss of BAP1 and PBRM1 expression, and demonstrates specific clinicopathological and genetic characteristics with BAP1 loss.
Misumi K; Hayashi A; Shibahara J; Arita J; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M
Histopathology; 2017 Apr; 70(5):766-774. PubMed ID: 27864835
[TBL] [Abstract][Full Text] [Related]
3. BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways.
Chen XX; Yin Y; Cheng JW; Huang A; Hu B; Zhang X; Sun YF; Wang J; Wang YP; Ji Y; Qiu SJ; Fan J; Zhou J; Yang XR
Cell Death Dis; 2018 Oct; 9(10):1036. PubMed ID: 30305612
[TBL] [Abstract][Full Text] [Related]
4. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma.
Ma B; Meng H; Tian Y; Wang Y; Song T; Zhang T; Wu Q; Cui Y; Li H; Zhang W; Li Q
BMC Cancer; 2020 Apr; 20(1):318. PubMed ID: 32293336
[TBL] [Abstract][Full Text] [Related]
5. Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection.
Guglielmi A; Ruzzenente A; Campagnaro T; Pachera S; Valdegamberi A; Nicoli P; Cappellani A; Malfermoni G; Iacono C
World J Surg; 2009 Jun; 33(6):1247-54. PubMed ID: 19294467
[TBL] [Abstract][Full Text] [Related]
6. A high level of integrin α6 expression in human intrahepatic cholangiocarcinoma cells is associated with a migratory and invasive phenotype.
Ding YB; Deng B; Huang YS; Xiao WM; Wu J; Zhang YQ; Wang YZ; Wu DC; Lu GT; Wu KY
Dig Dis Sci; 2013 Jun; 58(6):1627-35. PubMed ID: 23306848
[TBL] [Abstract][Full Text] [Related]
7. Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos.
Brandi G; Deserti M; Palloni A; Turchetti D; Zuntini R; Pedica F; Frega G; De Lorenzo S; Abbati F; Rizzo A; Di Marco M; Massari F; Tavolari S
Cancer Genet; 2020 Oct; 248-249():57-62. PubMed ID: 33093002
[TBL] [Abstract][Full Text] [Related]
8. Expression and prognostic value of PRL-3 in human intrahepatic cholangiocarcinoma.
Xu Y; Zhu M; Zhang S; Liu H; Li T; Qin C
Pathol Oncol Res; 2010 Jun; 16(2):169-75. PubMed ID: 19757198
[TBL] [Abstract][Full Text] [Related]
9. Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification?
Bagante F; Ruzzenente A; Conci S; Rusev BC; Simbolo M; Campagnaro T; Pawlik TM; Luchini C; Iacono C; Scarpa A; Guglielmi A
HPB (Oxford); 2019 Dec; 21(12):1648-1655. PubMed ID: 31122820
[TBL] [Abstract][Full Text] [Related]
10. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
[TBL] [Abstract][Full Text] [Related]
11. Loss of expression of BAP1 predicts longer survival in mesothelioma.
Farzin M; Toon CW; Clarkson A; Sioson L; Watson N; Andrici J; Gill AJ
Pathology; 2015 Jun; 47(4):302-7. PubMed ID: 25938359
[TBL] [Abstract][Full Text] [Related]
12. High-mobility group box 1 expression and lymph node metastasis in intrahepatic cholangiocarcinoma.
Xu YF; Ge FJ; Han B; Yang XQ; Su H; Zhao AC; Zhao MH; Yang YB; Yang J
World J Gastroenterol; 2015 Mar; 21(11):3256-65. PubMed ID: 25805932
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin-specific protease 14 expression associated with intrahepatic cholangiocarcinoma cell differentiation.
Chuensumran U; Saelee P; Punyarit P; Wongkham S; Pairojkul C; Chauin S; Petmitr S
Asian Pac J Cancer Prev; 2011; 12(3):775-9. PubMed ID: 21627382
[TBL] [Abstract][Full Text] [Related]
14. BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma.
Parasramka M; Yan IK; Wang X; Nguyen P; Matsuda A; Maji S; Foye C; Asmann Y; Patel T
Mol Cancer; 2017 Jan; 16(1):22. PubMed ID: 28122578
[TBL] [Abstract][Full Text] [Related]
15. The Prognostic Role of SOCS3 and A20 in Human Cholangiocarcinoma.
Wang Y; Wan M; Zhou Q; Wang H; Wang Z; Zhong X; Zhang L; Tai S; Cui Y
PLoS One; 2015; 10(10):e0141165. PubMed ID: 26485275
[TBL] [Abstract][Full Text] [Related]
16. Nuclear BAP1 loss is common in intrahepatic cholangiocarcinoma and a subtype of hepatocellular carcinoma but rare in pancreatic ductal adenocarcinoma.
Mosbeh A; Halfawy K; Abdel-Mageed WS; Sweed D; Rahman MHA
Cancer Genet; 2018 Aug; 224-225():21-28. PubMed ID: 29778232
[TBL] [Abstract][Full Text] [Related]
17. Survival analysis of intrahepatic cholangiocarcinoma after resection.
Cho SY; Park SJ; Kim SH; Han SS; Kim YK; Lee KW; Lee SA; Hong EK; Lee WJ; Woo SM
Ann Surg Oncol; 2010 Jul; 17(7):1823-30. PubMed ID: 20165987
[TBL] [Abstract][Full Text] [Related]
18. Expression and prognostic value of soluble CD97 and its ligand CD55 in intrahepatic cholangiocarcinoma.
Meng ZW; Liu MC; Hong HJ; Du Q; Chen YL
Tumour Biol; 2017 Mar; 39(3):1010428317694319. PubMed ID: 28345461
[TBL] [Abstract][Full Text] [Related]
19. Loss of nuclear BAP1 protein expression is a marker of poor prognosis in patients with clear cell renal cell carcinoma.
Minardi D; Lucarini G; Milanese G; Di Primio R; Montironi R; Muzzonigro G
Urol Oncol; 2016 Aug; 34(8):338.e11-8. PubMed ID: 27085487
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of aquaporin-1 in intrahepatic cholangiocarcinoma is related to tumor progression and mucin expression.
Aishima S; Kuroda Y; Nishihara Y; Taguchi K; Iguchi T; Taketomi A; Maehara Y; Tsuneyoshi M
Hum Pathol; 2007 Dec; 38(12):1819-25. PubMed ID: 17854859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
